Merit Medical Systems announced on 7 March 2013 that it has received the CE mark to market in the European Union its line of Embosphere microspheres for embolization of the prostate gland for relief of symptoms related to benign prostatic hyperplasia.
At the ACC, 24-month data for the Symplicity renal denervation system showed that patients (number = 40) initially randomised to the intervention, compared with their baseline levels, had a sustained sustained significant drop in blood pressure (-29/-10 mmHg; p<0.01]).
Cordis announced it has completed the acquisition of Flexible Stenting Solutions, a leading developer of innovative flexible peripheral arterial, venous and biliary stents on 12 March 2013.
On 8 March 2013, Philips introduced three new imaging systems to help radiology departments increase both the number of patients and range of clinical exams they can handle. Philips is continuing the Imaging 2.0 journey to deliver greater collaboration and integration, increased patient focus and improved economic value. The imaging systems were showcased at the European Congress of Radiology (ECR) 2013 (7–11 March Vienna, Austria), all three systems combine the capabilities for high patient throughput with the functionality and advanced clinical imaging applications.
Luminos Fusion, according to the company is has two-in-one functionality, with flat panel detector technology allows more effective use of fluoroscopy equipment in routine medical care. The flat panel detector enables faster examinations and patient throughput compared to the mid-range image intensifiers that have been available up to now.
Toshiba announced on 8 March 2013 a scientific co-operation with VU medisch centrum (VUmc) for research into dementia and neuro-degenerative conditions.
Rox Medical has announced the enrolment of the first two Irish patients, at Beaumont and Mater Private Hospitals, in the CONTROL-HTN randomised controlled trial of its Rox Flow procedure for the treatment of resistant hypertension.
Royal Philips Electronics has announced that it has received 510(k) clearance from the FDA to market its EchoNavigator live image-guidance tool, which is designed to help interventional cardiologists and cardiac surgeons to perform minimally-invasive structural heart disease repairs by providing an integrated view of live X-ray and 3D ultrasound images.
The online meeting registration is open for the Society of Interventional Radiology s Annual Scientific Meeting 13–18 April at the Ernest N Morial Convention Center in New Orleans, USA. “The meeting s theme, “Interventional Radiology reaching out,” illustrates the many ways the Annual Scientific Meeting provides valuable education to attendees across a broad range of diverse clinical interests and practice settings,” said Gary P Siskin, professor and chair of the department of radiology, Albany Medical College, Albany, New York, USA, and the meeting s scientific programme chair. “Annual Scientific Meeting attendees come from all areas: they are community or university-based physicians, physician assistants, nurse practitioners and radiology assistants, nurses, technologists, hospital administrators and industry partners. To complement our theme of inclusion, we have designed sessions that will meet the educational needs of all these various groups,” Siskin added.
Surefire Medical’s new infusion system maximises delivery of drugs directly to the tumour site while minimising potential damage to non-target organs, according to a new study. The ability to more safely and efficiently deliver embolic agents to target tumours locally marks a significant advance in radiation oncology procedures and in the treatment of liver cancer.
ReCor Medical has announced the start of ACHIEVE, a 50-patient post-market study of the company’s CE marked next-generation, ultrasound-based renal denervation system (Paradise) that will be conducted across multiple sites in Europe. According to a company press release, the Paradise system is a minimally invasive 6Fr over-the-wire ultrasound device for treating resistant hypertension. The first two patients in the study have been enrolled at the Thoraxcenter, Rotterdam, The Netherlands. Both patients were treated quickly with no device or procedural complications.
St Jude Medical, the company behind the Enlightn renal denervation system, has announced that its new study—Enlightnment—will investigate the long-term effects of renal denervation in patients with resistant hypertension to see if the treatment can reduce the risk of major cardiovascular events (such as myocardial infarction) as well as lower blood pressure.
On the 26 February 2013 Surefire Medical, the developer of a new class of infusion systems designed to maximise targeted delivery of embolization agents without reflux, announced CE mark approval for its Surefire Infusion System ST/LT and Surefire Specialty Catheters. The company will launch its latest products in Europe during the second quarter 2013.
The Diagnostic Center for Disease, Florida, USA, in conjunction with PanAm HIFU, announced data results on 5 March 2013 showing a 95% cure rate with high intensity focused ultrasound (HIFU) in more than 200 patients at more than 7 years post treatment.
On 1 March 2013, Coding Strategies, who produce consulting and education for physician and outpatient medical coding, compliance and ICD-10-CM for specialty-specific content, launched this week two new resources dedicated to radiology and oncology HCPCS codes—the HCPCS Radiology Resource and the HCPCS Oncology Resource. According to the company, these easy-to-use reference tools are designed to provide quick access to the HCPCS codes for radiology or infusion centre practices and departments.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos